

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 15, 2025 (the “**Prospectus**”) of QingSong Health Corporation (轻松健康集团) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited and China Merchants Securities (HK) Co., Limited act as the Joint Sponsors, Sponsor-Overall Coordinators and Overall Coordinators. In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the Shares could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to term and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



**QingSong Health Corporation**  
**轻松健康集团**

*(Incorporated in the Cayman Islands with limited liability)*

**Global Offering**

|   |          |   |
|---|----------|---|
| <b>Total number of Offer Shares under the Global Offering</b> | <b>:</b> | <b>26,540,000 Shares (subject to the Over-allotment Option)</b>   |
| <b>Number of Hong Kong Offer Shares</b>                       | <b>:</b> | <b>2,654,000 Shares (subject to reallocation)</b>   |
| <b>Number of International Offer Shares</b>                   | <b>:</b> | <b>23,886,000 Shares (subject to reallocation and the Over-allotment Option)</b>  |
| <b>Offer Price</b>  | <b>:</b> | <b>HK\$22.68 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)</b> |
| <b>Nominal value</b>  | <b>:</b> | <b>US\$0.0001 per Share</b>   |
| <b>Stock code</b>   | <b>:</b> | <b>2661</b>   |

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*



*Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager*



*Joint Bookrunner and Joint Lead Manager*



---

# IMPORTANT

---

## **IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS**

**We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus to the public in relation to the Hong Kong Public Offering.**

**The Prospectus is available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at <https://www.qingsonghealth.com/>. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.**

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online via the **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk); or
- (2) apply electronically through the **HKSCC EIPO** channel by instructing your **broker** or **custodian** who is an HKSCC Participant to submit **electronic application instructions** via FINI to apply for the Hong Kong Offer Shares on your behalf.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

**If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that this prospectus is available online at the website addresses above.**

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or the **HKSCC EIPO** channel must be for a minimum of 200 Hong Kong Offer Shares and in one of the numbers set out in the table.

If you are applying through the **White Form eIPO** service, you may refer to the table below for the amount payable for the number of Hong Kong Offer Shares you have selected. You must pay the respective amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, your **broker** or **custodian** may require you to pre-fund your application in such amount as determined by the **broker** or **custodian**, based on the applicable laws and regulations in Hong Kong. You are responsible for complying with any such pre-funding requirement imposed by your broker or custodian with respect to the Hong Kong Offer Shares you applied for.

| No. of<br>Hong Kong<br>Offer Shares<br>applied for | Amount<br>payable <sup>(2)</sup> on<br>application<br>HK\$ | No. of<br>Hong Kong<br>Offer Shares<br>applied for | Amount<br>payable <sup>(2)</sup> on<br>application<br>HK\$ | No. of<br>Hong Kong<br>Offer Shares<br>applied for | Amount<br>payable <sup>(2)</sup> on<br>application<br>HK\$ | No. of<br>Hong Kong<br>Offer Shares<br>applied for | Amount<br>payable <sup>(2)</sup> on<br>application<br>HK\$ |
|--|--|--|--|--|--|--|--|
| 200  | 4,581.75   | 3,000  | 68,726.18  | 40,000   | 916,349.11   | 500,000  | 11,454,363.90  |
| 400  | 9,163.48   | 4,000  | 91,634.92  | 50,000   | 1,145,436.39   | 550,000  | 12,599,800.29  |
| 600  | 13,745.24  | 5,000  | 114,543.64   | 100,000  | 2,290,872.78   | 600,000  | 13,745,236.68  |
| 800  | 18,326.99  | 6,000  | 137,452.36   | 150,000  | 3,436,309.16   | 700,000  | 16,036,109.45  |
| 1,000  | 22,908.72  | 7,000  | 160,361.10   | 200,000  | 4,581,745.55   | 800,000  | 18,326,982.25  |
| 1,200  | 27,490.47  | 8,000  | 183,269.82   | 250,000  | 5,727,181.96   | 900,000  | 20,617,855.02  |
| 1,400  | 32,072.22  | 9,000  | 206,178.55   | 300,000  | 6,872,618.35   | 1,000,000  | 22,908,727.80  |
| 1,600  | 36,653.96  | 10,000   | 229,087.27   | 350,000  | 8,018,054.74   | 1,100,000  | 25,199,600.58  |
| 1,800  | 41,235.71  | 20,000   | 458,174.56   | 400,000  | 9,163,491.12   | 1,200,000  | 27,490,473.35  |
| 2,000  | 45,817.45  | 30,000   | 687,261.83   | 450,000  | 10,308,927.51  | 1,327,000 <sup>(1)</sup>                           | 30,399,881.78  |

(1) Maximum number of Hong Kong Offer Share you may apply for.

(2) The amount payable is inclusive of brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) and the SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy are paid to the Stock Exchange (in the case of the SFC transaction levy, collected by the Stock Exchange on behalf of the SFC; and in the case of the AFRC transaction levy, collected by the Stock Exchange on behalf of the AFRC).

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

## THE LISTING APPLICATION

We have applied to the Stock Exchange for the granting of the listing of, and permission to deal in, the Shares to be issued by the Company pursuant to the Global Offering (including the Shares which may be issued pursuant to the exercise of the Over-allotment Option) and the Shares to be issued pursuant to the Pre-IPO Share Option Scheme.

## STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 2,654,000 Shares (subject to reallocation), representing approximately 10% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 23,886,000 Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Chapter 4.14 of the Guide for New Listing Applicants issued by the Stock Exchange, the Overall Coordinators (for themselves and on behalf of the Underwriters) may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Chapter 4.14 of the Guide for New Listing Applicants issued by the Stock Exchange, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering will be 1,327,000 Offer Shares, so that the total number of Offer Shares for subscription under the Hong Kong Public Offering will increase up to 3,981,000 Shares, representing approximately 15% of the number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

In connection with the Global Offering, it is expected that the Company will grant the Over-allotment Option to the International Underwriters, which will be exercisable by the Overall Coordinators (for themselves and on behalf of the International Underwriters).

Pursuant to the Over-allotment Option, the International Underwriters have the right, exercisable by the Overall Coordinators (on behalf of the International Underwriters) at any time from the Listing Date to the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to 3,981,000 Offer Shares, representing approximately 15.0% of the maximum number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering, to cover over-allocations in the International Offering, if any. In the event the Over-Allotment Option is exercised, an announcement will be made on the website of the Company at <https://www.qingsonghealth.com> and the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk).

## PRICING

The Offer Price will be HK\$22.68 per Offer Share, unless otherwise announced, as further explained below. Applicants under the Hong Kong Public Offering are required to pay, on application, the Offer Price of HK\$22.68 per Offer Share for each Hong Kong Offer Share together with brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, amounting to a total of HK\$4,581.75 for one board lot of 200 Offer Shares. Further details are set out in the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus.

## EXPECTED TIMETABLE

*If there is any change in the following expected timetable of the Hong Kong Public Offering, we will issue an announcement in Hong Kong to be published on our Company’s website at <https://www.qingsonghealth.com> and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).*

|   |  |
|---|--|
| Hong Kong Public Offering commences . . . . .   | 9:00 a.m. on<br>Monday, December 15, 2025    |
| Latest time for complete electronic applications under the <b>White Form eIPO</b> service through the designated website at <a href="http://www.eipo.com.hk">www.eipo.com.hk</a> . . . . .  | 11:30 a.m. on<br>Thursday, December 18, 2025 |
| Application lists open . . . . .  | 11:45 a.m. on<br>Thursday, December 18, 2025 |
| Latest time for (a) completing payment of <b>White Form eIPO</b> applications by effecting internet banking transfer(s) or PPS payment transfer(s) and (b) giving <b>electronic application instructions</b> to HKSCC . . . . .   | 12:00 noon on<br>Thursday, December 18, 2025 |
| If you are instructing your <b>broker</b> or <b>custodian</b> who is a HKSCC Participant will give <b>electronic application instructions</b> on your behalf through HKSCC’s FINI system in accordance with your instruction, you are advised to contact your <b>broker</b> or <b>custodian</b> for the earliest and latest time for giving such instructions as this may vary by <b>broker</b> or <b>custodian</b> . |  |
| Application lists close . . . . .   | 12:00 noon on<br>Thursday, December 18, 2025 |



Announcement of the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering, the basis of allocation of the Hong Kong Offer Shares to be published on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and on our Company's website at <https://www.qingsonghealth.com> at or before. ....

11:00 p.m. on  
Monday, December 22, 2025

The results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- in the announcement to be posted on our website and the website of the Stock Exchange at <https://www.qingsonghealth.com> and [www.hkexnews.hk](http://www.hkexnews.hk), respectively .....

at or before 11:00 p.m. on  
Monday, December 22, 2025

- from the designated results of allocation at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: <http://www.eipo.com.hk/eIPOAllotment>) with a "search by ID" function from. ....

11:00 p.m. on  
Monday, December 22, 2025 to  
12:00 midnight on  
Sunday, December 28, 2025

- from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on .....

Tuesday, December 23, 2025,  
Wednesday, December 24, 2025,  
Monday, December 29, 2025 and  
Tuesday, December 30, 2025  
(except weekend and  
public holiday in Hong Kong)

Share certificates in respect of wholly or partially successful applications to be despatched or deposited into CCASS on or before .....

Monday, December 22, 2025

**White Form** e-Refund payment instructions/refund checks in respect of (i) wholly successful applications (if applicable) and (ii) wholly or partially unsuccessful application under the Hong Kong Public Offering to be dispatched/collected on or before .....

Tuesday, December 23, 2025

Dealings in the Shares on the Stock Exchange expected to commence at .....

9:00 a.m. on  
Tuesday, December 23, 2025

*Note: All dates and times refer to Hong Kong local dates and times, except as otherwise stated.*

## SETTLEMENT

Subject to the granting of listing of, and permission to deal in, the Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, our Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Hong Kong Stock Exchange or any other date as determined by HKSCC. Settlement of any transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and HKSCC Operational Procedures in effect from time to time. All necessary arrangements have been made for the Shares to be admitted into CCASS. Investors should seek the advice of their stockbroker or other professional advisers for details of the settlement arrangements as such arrangements may affect their rights and interests.

## ELECTRONIC APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 a.m. on Monday, December 15, 2025 and end at 12:00 noon on Thursday, December 18, 2025 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

| Application Channel | Platform  | Target Investors   | Application Time  |
|---------------------|---|--|---|
| White Form eIPO     | <a href="http://www.eipo.com.hk">www.eipo.com.hk</a>  | Applicants who would like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.   | From 9:00 a.m. on Monday, December 15, 2025 to 11:30 a.m. on Thursday, December 18, 2025, Hong Kong time.<br><br>The latest time for completing full payment of application monies will be 12:00 noon on Thursday, December 18, 2025, Hong Kong time. |
| HKSCC EIPO channel  | Your <b>broker</b> or <b>custodian</b> who is a HKSCC Participant will submit <b>electronic application instruction(s)</b> on your behalf through HKSCC's FINI system in accordance with your instruction | Applicants who would not like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account. | Contact your <b>broker</b> or <b>custodian</b> for the earliest and latest time for giving such instructions, as this may vary by <b>broker</b> or <b>custodian</b> .   |



The **White Form eIPO** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

**Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for the White Form eIPO service.**

## **PUBLICATION OF RESULTS**

The Company expects to announce the level of indications of interest in the Global Offering, the level of applications in the Hong Kong Public Offering and the basis of allocations of Hong Kong Offer Shares on the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company’s website at <https://www.qingsonghealth.com/> by no later than 11:00 p.m. on Monday, December 22, 2025 (Hong Kong time).

The results of allocations and the identification document numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering are not fulfilled in accordance with “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded without interest.

No temporary document of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application. Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, December 23, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” has not been exercised. Investors who trade Shares prior to the receipt of Share certificates or the Share certificates becoming valid do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, December 23, 2025, it is expected that dealings in the Shares on the Stock Exchange will commence on Tuesday, December 23, 2025. The Shares will be traded in board lots of 200 each and the stock code will be 2661.

This announcement is available for viewing on the website of the Company at <https://www.qingsonghealth.com/> and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

By order of the Board  
**QingSong Health Corporation**  
轻松健康集团  
**YANG Yin**

*Chairlady of the Board, Executive Director and Chief Executive Officer*

People's Republic of China, December 15, 2025

*As of the date of this announcement, the board of directors of the Company named in the Prospectus comprises: (i) Ms. YANG Yin and Ms. WANG Jing as executive Directors; (ii) Mr. ZHAO Yuping, Mr. ZHENG Kaihuan and Mr. WU Bin as non-executive Directors; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Mr. BAI Kun as proposed independent non-executive Directors (effective upon Listing).*